Patents by Inventor George M. Carrera, Jr.

George M. Carrera, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biphenyl hydroxamate inhibitors of matrix metalloproteinases
    Patent number: 5665777
    Abstract: Compounds of formula ##STR1## or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF.alpha. secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF.alpha. secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF.alpha. secretion.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: September 9, 1997
    Assignee: Abbott Laboratories
    Inventors: Stephen W. Fesik, James B. Summers, Jr., Steven K. Davidsen, George S. Sheppard, Douglas H. Steinman, George M. Carrera, Jr., Alan Florjancic, James H. Holms
  • Indole piperazine platelet activating factor antagonists
    Patent number: 5654305
    Abstract: The present invention provides compounds of formula ##STR1## wherein Y is >C.dbd.O or >S(O).sub.t wherein t is 1 or 2 and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, rhinitis, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.
    Type: Grant
    Filed: July 2, 1996
    Date of Patent: August 5, 1997
    Assignee: Abbott Laboratories
    Inventors: George S. Sheppard, Steven K. Davidsen, James B. Summers, George M. Carrera, Jr.
  • Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
    Patent number: 5567711
    Abstract: The present invention provides compounds of formula ##STR1## and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: October 22, 1996
    Assignee: Abbott Laboratories
    Inventors: George S. Sheppard, Steven K. Davidsen, James B. Summers, George M. Carrera, Jr.
  • Platelet activating factor antagonists: imidazopyridine indoles
    Patent number: 5486525
    Abstract: The present invention relates to compounds of formula ##STR1## and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: January 23, 1996
    Assignee: Abbott Laboratories
    Inventors: James B. Summers, Jr., Steven K. Davidsen, Michael L. Curtin, H. Robin Heyman, George S. Sheppard, Lianhong Xu, George M. Carrera, Jr., Robert B. Garland
  • Platelet activating factor antagonists
    Patent number: 5459152
    Abstract: Indole compounds substituted at the 3-position by a 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]thiazole, 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]oxazole, or 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]pyrrole group are potent antagionists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointesinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: October 17, 1995
    Assignee: Abbott Laboratories
    Inventors: James B. Summers, Steven K. Davidsen, James H. Holms, Daisy Pireh, H. Robin Heyman, Michael B. Martin, Douglas H. Steinman, George S. Sheppard, George M. Carrera, Jr.
  • Isoxazole, isothiazole and pyrazole compounds that enhance cognitive function
    Patent number: 5409946
    Abstract: Novel isoxazole isothiazole and pyrazole compounds of the formula: ##STR1## wherein A, R.sup.1, and R.sup.2 are specifically defined, or pharmaceutical salts thereof, are selective and potent cholinergic ligands at neuronal nicotinic receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function, as well as in the treatment of alcohol intoxication and petit real absence epilepsy.
    Type: Grant
    Filed: September 8, 1993
    Date of Patent: April 25, 1995
    Assignee: Abbott Laboratories
    Inventors: David S. Garvey, George M. Carrera, Jr., Stephen P. Arneric, Youe-Kong Shue, Nan-Horng Lin, Yun He, Edmund L. Lee, Suzanne A. Lebold
  • Platelet activating factor antagonists
    Patent number: 5382670
    Abstract: Indole compounds substituted at the 1- or 3-position by a (pyrid-3-yl)thiazolid-4-yl)alkyl-, (pyrid-3-yl)thiazolid-4-oyl)-, (pyrid-3-yl)dithiolan-4-yl)alkyl- or (pyrid-3-yl)dithiolan-4-oyl)- group are potent inhibitors of PAF and are useful in the treatment of PAF-related disorders including septic shock, respiratory distress syndrome, acute inflammation, delayed cellular immunity, parturtition, fetal lung maturation, and cellular differentiation.
    Type: Grant
    Filed: July 7, 1993
    Date of Patent: January 17, 1995
    Assignee: Abbott Laboratories
    Inventors: James B. Summers, George S. Sheppard, James G. Phillips, Daisy Pireh, Douglas H. Steinman, Paul D. May, Denise E. Guinn, H. Robin Heyman, George M. Carrera, Jr., Steven K. Davidsen